Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.

Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X, Nicoloso MS, Wu SY, Almeida MI, Bottsford-Miller J, Pecot CV, Zand B, Matsuo K, Shahzad MM, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Calin GA.

Cancer Discov. 2013 Nov;3(11):1302-15. doi: 10.1158/2159-8290.CD-13-0159. Epub 2013 Sep 3.

2.

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK.

Cancer Res. 2005 Aug 1;65(15):6910-8.

3.

MicroRNA 520d-3p inhibits gastric cancer cell proliferation, migration, and invasion by downregulating EphA2 expression.

Li R, Yuan W, Mei W, Yang K, Chen Z.

Mol Cell Biochem. 2014 Nov;396(1-2):295-305. doi: 10.1007/s11010-014-2164-6. Epub 2014 Jul 26.

PMID:
25063221
4.

Dual targeting of EphA2 and FAK in ovarian carcinoma.

Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK.

Cancer Biol Ther. 2009 Jun;8(11):1027-34. Epub 2009 Jun 24.

5.

Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.

Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G.

Clin Cancer Res. 2013 Apr 1;19(7):1806-15. doi: 10.1158/1078-0432.CCR-12-2764. Epub 2013 Feb 5.

6.

Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo.

Yuan W, Chen Z, Chen Z, Wu S, Guo J, Ge J, Yang P, Huang J.

Neoplasma. 2012;59(1):105-13.

PMID:
22103904
7.

Liposomal siRNA for ovarian cancer.

Mangala LS, Han HD, Lopez-Berestein G, Sood AK.

Methods Mol Biol. 2009;555:29-42. doi: 10.1007/978-1-60327-295-7_3.

PMID:
19495686
8.

Sustained small interfering RNA delivery by mesoporous silicon particles.

Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M.

Cancer Res. 2010 May 1;70(9):3687-96. doi: 10.1158/0008-5472.CAN-09-3931.

9.

Small RNAs deliver a blow to ovarian cancer.

Kasinski A, Slack FJ.

Cancer Discov. 2013 Nov;3(11):1220-1. doi: 10.1158/2159-8290.CD-13-0667.

10.

Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.

Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK.

Cancer Biol Ther. 2006 Dec;5(12):1708-13. Epub 2006 Dec 30.

PMID:
17106249
11.

EphA2 as a target for ovarian cancer therapy.

Landen CN, Kinch MS, Sood AK.

Expert Opin Ther Targets. 2005 Dec;9(6):1179-87. Review.

PMID:
16300469
12.

Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2006 Aug 15;12(16):4916-24.

13.

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.

Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.

J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70.

14.

EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.

Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK.

J Natl Cancer Inst. 2009 Sep 2;101(17):1193-205. doi: 10.1093/jnci/djp231. Epub 2009 Jul 29.

15.

Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist.

Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, Zhao H, Ruggeri B.

Cancer Res. 2004 Feb 1;64(3):910-9.

16.

[Influence of EphA2 siRNA transfection on the biological behavior of human ovarian carcinoma cell].

Han LP, Li MM, Zhang XX, Geng LN, Suo ZH.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2013 Nov;44(6):877-81. Chinese.

PMID:
24490493
17.

Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.

Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK.

Clin Cancer Res. 2011 Apr 15;17(8):2250-9. doi: 10.1158/1078-0432.CCR-10-2718. Epub 2011 Mar 18. Erratum in: Clin Cancer Res. 2013 Mar 1;19(5):1305.

18.

Therapeutic Targeting of ATP7B in Ovarian Carcinoma.

Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK.

Clin Cancer Res. 2009 Jun 1;15(11):3770-80. doi: 10.1158/1078-0432.CCR-08-2306. Epub 2009 May 26.

19.

Targeting c-MYC in Platinum-Resistant Ovarian Cancer.

Reyes-González JM, Armaiz-Peña GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mejía PE.

Mol Cancer Ther. 2015 Oct;14(10):2260-9. doi: 10.1158/1535-7163.MCT-14-0801. Epub 2015 Jul 30.

PMID:
26227489
20.

The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC Jr.

J Natl Cancer Inst. 2011 Sep 21;103(18):1403-22. doi: 10.1093/jnci/djr280. Epub 2011 Aug 2.

Items per page

Supplemental Content

Write to the Help Desk